Pular para o conteúdo principal
Ranking Invest

MNPR - Monopar Therapeutics Inc.

Segmento: HealthcareMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Análise Ranking Invest

Valuation estimado
-$ 1.11 Bi
Valor de Mercado
$ 740.15 Mi
Desconto (AV)-166.6%
IVR
-1.50A companhia vale -1,50 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-1.68O valuation alternativo equivale a -168% do valor de mercado da companhia.
MLL
-1.68O lucro líquido dos controladores em 16 trimestres equivale a -168% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 130.85 Mi

Dívida Líquida

-$ 52.76 Mi

L4T

-$ 17.84 Mi

Indicadores Básicos

ROE

-13.64%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

C0.38

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

F-4.97

Margem

D0.00

Índices de Endividamento

DIV/PAT

-0.40

DIV/L4T

2.96

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.